Werewolf Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	134.34	129.32	158.74	92.78	18.1
Cash & Cash Equivalents	134.34	129.32	158.74	92.78	18.1
Cash Growth	3.89%	-18.54%	71.10%	412.47%	-
Receivables	1.35	6.93	0	0	0
Other Current Assets	2.68	3.96	2.33	0.14	-0.04
Total Current Assets	138.37	140.2	161.07	92.91	18.06
Property, Plant & Equipment	14.85	17.45	16.33	3.12	3.41
Long-Term Investments	21.02	1.21	0	0	0
Other Long-Term Assets	0.59	1.38	1.86	0.36	0.21
Total Long-Term Assets	36.46	20.05	18.18	3.48	3.62
Total Assets	174.83	160.25	179.25	96.4	21.68
Accounts Payable	1.34	1.22	2.04	1.02	0.63
Deferred Revenue	1.34	7.66	0	0	0
Current Debt	8.28	2.08	1.07	0.68	0.6
Other Current Liabilities	8.43	13.02	8.77	3.59	0.82
Total Current Liabilities	19.38	23.99	11.87	5.28	2.04
Long-Term Debt	43.65	12.6	14.59	1.86	2.54
Other Long-Term Liabilities	0.43	1.32	0	0.03	7.32
Total Long-Term Liabilities	44.08	13.92	14.59	1.9	9.87
Total Liabilities	63.46	37.91	26.46	7.18	11.91
Total Debt	51.92	14.68	15.66	2.54	3.14
Debt Growth	253.60%	-6.24%	516.33%	-19.00%	-
Retained Earnings	-344.07	-306.71	-252.9	-51.87	-24.41
Shareholders' Equity	111.37	122.34	152.79	-51.86	-24.3
Net Cash / Debt	82.42	114.63	143.08	90.24	14.97
Net Cash / Debt Growth	-28.10%	-19.88%	58.56%	502.90%	-
Net Cash Per Share	2.31	3.97	7.75	89.79	23.39
Working Capital	118.99	116.21	149.19	87.63	16.02
Book Value Per Share	3.12	4.24	8.28	-51.60	-37.98

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).